STOCKHOLM, SE / ACCESS Newswire / August 5, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that ...

Alzheimer’s Disease (AD), that steal away mental faculties and debilitates day to day life of patients, may soon have a game-changing path for not just its treatment, but also ...

A new study shows that the way amyloid proteins—implicated in Alzheimer's disease—assemble into fibrils can be significantly ...

Unlike most cells in the human body, neurons—the functional cells of our nervous system—cannot typically replace themselves ...

Our genes significantly influence how we perceive smells, impacting everything from our favorite scents to reactions to ...

The new drug has already passed Phase 1 safety trials in humans, making it a "strong candidate" for future PTSD treatments.

Anavex Life Sciences Corp. (NASDAQ:AVXL) announced the latest findings on Thursday for blarcamesine, an oral small molecule ...

Spear Bio, a biotechnology company pioneering homogeneous ultrasensitive immunoassay technology, today announced the ...

University of Michigan researchers found that sugar metabolism in neurons influences whether axons degrade or survive after ...

Anavex's blarcasemine met its primary endpoints, improving cognition and function over a four year period in early-stage Alzheimer’s patients.